CD209 and cancer: The binding with various anti-cancer drugs targeted to specific cancer subtype could overcome the limitation of the mannan-based probes (targeting to DC-SIGN only), increase their efficiency and conjugated anti-cancer drugs could benefit from the mannan-based probes versatility, targeting via EPR effect and possibility of local anti-cancer drug release in response to various stimuli (which would depend on the type of conjugation).